



## IBA to recruit 400 new employees

*IBA to expand workforce for the installation and maintenance of proton therapy systems*

**Louvain-la-Neuve, Belgium, January 29th, 2016** - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces it intends to hire 400 new employees in 2016.

Following the proton therapy orders booked over the last few years globally, IBA is launching an international hiring plan to recruit 400 new employees over the year. Approximately one half of these will be based in Louvain-la-Neuve, Belgium, with the remainder to be divided across the USA, Europe and Asia. The majority of hires will be field service engineers, responsible for the installation and maintenance of proton therapy systems.

It is clear from the increased number of patients treated and proton therapy rooms sold that the market is entering a phase of growth. While proton therapy today only represents about one percent of radiotherapy treatments, studies estimate that more than 17 percent of radiotherapy patients would benefit from proton therapy treatment.

**Frederic Nolf, Chief Human Resources Officer of IBA, comments:** *"2015 was a significant year for IBA with strong business results matched by the continued growth of the proton therapy market. As a result, IBA intends to increase its workforce over the coming year so that we can service our booked demand. This intensive hiring plan is aimed at maintaining IBA at the forefront of scientific and technological innovation in proton therapy as well as attracting and retaining the best talent to support the future success of the Company. I am proud that IBA employees share this passion and use their knowledge and experience in a rewarding work environment to make a difference in the fight against cancer."*

\*\*\*end\*\*\*

### **About Proton Therapy**

Proton therapy is considered to be one of the most advanced treatments available in the fight against cancer. With the precision that proton therapy offers, it is possible to target the tumor more effectively while limiting the side effects of the treatment. Protons deposit the majority of their energy within a precisely controlled zone, directly in the tumor while limiting the impact on healthy tissues surrounding the tumor.



Proton therapy is particularly appropriate for the treatment of eye and brain cancers, tumors close to the brain stem and spinal cord as well as prostate, liver, lung cancers. Proton therapy is also extremely well-suited for the treatment of pediatric cancers.

**About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**For further information please contact:**

**IBA**

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[Communication@iba-group.com](mailto:Communication@iba-group.com)

Frédéric Nolf  
Chief Human Resources Officer  
+32 10 475 890  
[Communication@iba-group.com](mailto:Communication@iba-group.com)

**For media enquiries:**

**Consilium Strategic Communications**

Amber Fennell, Matthew Neal, Ivar Milligan  
+44 (0) 20 3709 5700  
[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)

**Rx Communications Group (US)**

Melody Carey  
+ 1 917 322 2571  
[mcarey@RxIR.com](mailto:mcarey@RxIR.com)